FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206496593> ?p ?o ?g. }

• W3206496593 endingPage "62" @default.
• W3206496593 startingPage "47" @default.
• W3206496593 abstract "The use of immune checkpoint inhibitors (ICIs), especially anti-programmed cell death 1 (PD1) and anti-programmed cell death ligand 1 (PD-L1), has changed practices in oncology, becoming a new standard of care in first or subsequent lines for several cancer subtypes. Recent data have highlighted the ability of standard chemotherapy to enhance immunogenicity and/or to break immunoresistance of the tumour and its microenvironment, leading to a rationale for the use of ICIs in combination with the standard chemotherapy regimen to improve efficacy of cancer treatment. Here, we propose to review randomised clinical trials evaluating concomitant administration of ICIs and chemotherapy, to assess clinical efficacy and safety profiles in advanced solid tumours. Association of these two modes of action on treatments has shown improved overall survival and better objective response rates than standard chemotherapy, especially in first-line treatment of non-small cell lung cancer (NSCLC) and for PD1/PD-L1 enriched tumours, highlighting a potential synergistic effect of this treatment combination in certain tumour types. However, improved survival results with the use of anti-PD-L1 avelumab as a maintenance schedule for bladder cancer raises the question of the most appropriate approach between sequential and concomitant administration of chemoimmunotherapy. To date, no trials have compared in a head-to-head protocol the administration of concomitant chemoimmunotherapy with chemotherapy, used for tumour debulking, followed by administration of ICIs. Regarding the tolerance profile, no new safety signals were found with the combination tested to date. Interestingly, recent results have shown an improved Progression Free survival 2 (PFS2) (defined as the progression after the next line of therapy) in head-and-neck cancers or NSCLC after a first-line pembrolizumab-chemotherapy combination, suggesting a potential long-lasting effect of ICIs when used in combination in the first-line setting." @default.
• W3206496593 created "2021-10-25" @default.
• W3206496593 creator A5001765244 @default.
• W3206496593 creator A5019500272 @default.
• W3206496593 creator A5040832651 @default.
• W3206496593 creator A5044193192 @default.
• W3206496593 creator A5044691418 @default.
• W3206496593 creator A5047145634 @default.
• W3206496593 creator A5062289178 @default.
• W3206496593 creator A5073523132 @default.
• W3206496593 creator A5074983579 @default.
• W3206496593 creator A5085575415 @default.
• W3206496593 date "2021-11-01" @default.
• W3206496593 modified "2023-10-11" @default.
• W3206496593 title "Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review" @default.
• W3206496593 cites W1966999467 @default.
• W3206496593 cites W1973091654 @default.
• W3206496593 cites W2009720434 @default.
• W3206496593 cites W2033708244 @default.
• W3206496593 cites W2034751554 @default.
• W3206496593 cites W2044720517 @default.
• W3206496593 cites W2056631765 @default.
• W3206496593 cites W2079068389 @default.
• W3206496593 cites W2099918668 @default.
• W3206496593 cites W2101156795 @default.
• W3206496593 cites W2104347254 @default.
• W3206496593 cites W2108927999 @default.
• W3206496593 cites W2120426523 @default.
• W3206496593 cites W2123363005 @default.
• W3206496593 cites W2137614346 @default.
• W3206496593 cites W2137723371 @default.
• W3206496593 cites W2142644858 @default.
• W3206496593 cites W2143994426 @default.
• W3206496593 cites W2158545805 @default.
• W3206496593 cites W2164281389 @default.
• W3206496593 cites W2169178790 @default.
• W3206496593 cites W2198093519 @default.
• W3206496593 cites W2210453860 @default.
• W3206496593 cites W2346108121 @default.
• W3206496593 cites W2473218705 @default.
• W3206496593 cites W2527905628 @default.
• W3206496593 cites W2528083170 @default.
• W3206496593 cites W2529484692 @default.
• W3206496593 cites W2567564314 @default.
• W3206496593 cites W2588916311 @default.
• W3206496593 cites W2607272476 @default.
• W3206496593 cites W2743577629 @default.
• W3206496593 cites W2747107882 @default.
• W3206496593 cites W2753529762 @default.
• W3206496593 cites W2755210674 @default.
• W3206496593 cites W2766923414 @default.
• W3206496593 cites W2777192533 @default.
• W3206496593 cites W2796582438 @default.
• W3206496593 cites W2805193692 @default.
• W3206496593 cites W2805354595 @default.
• W3206496593 cites W2806213952 @default.
• W3206496593 cites W2887187316 @default.
• W3206496593 cites W2887577080 @default.
• W3206496593 cites W2892005194 @default.
• W3206496593 cites W2892640821 @default.
• W3206496593 cites W2893960509 @default.
• W3206496593 cites W2897422388 @default.
• W3206496593 cites W2903493423 @default.
• W3206496593 cites W2907564726 @default.
• W3206496593 cites W2921768356 @default.
• W3206496593 cites W2924289105 @default.
• W3206496593 cites W2946386783 @default.
• W3206496593 cites W2972212968 @default.
• W3206496593 cites W2976652879 @default.
• W3206496593 cites W2976744492 @default.
• W3206496593 cites W2977392388 @default.
• W3206496593 cites W2979272694 @default.
• W3206496593 cites W2986633517 @default.
• W3206496593 cites W2995826615 @default.
• W3206496593 cites W3006930853 @default.
• W3206496593 cites W3009099064 @default.
• W3206496593 cites W3014160477 @default.
• W3206496593 cites W3015816649 @default.
• W3206496593 cites W3017322331 @default.
• W3206496593 cites W3024551702 @default.
• W3206496593 cites W3030178583 @default.
• W3206496593 cites W3031475478 @default.
• W3206496593 cites W3043703771 @default.
• W3206496593 cites W3047618013 @default.
• W3206496593 cites W3087393791 @default.
• W3206496593 cites W3087464965 @default.
• W3206496593 cites W3087784988 @default.
• W3206496593 cites W3088611248 @default.
• W3206496593 cites W3089110714 @default.
• W3206496593 cites W3091399767 @default.
• W3206496593 cites W3091570384 @default.
• W3206496593 cites W3092384992 @default.
• W3206496593 cites W3109853980 @default.
• W3206496593 cites W3118442307 @default.
• W3206496593 cites W3121907365 @default.
• W3206496593 cites W3127182916 @default.
• W3206496593 cites W3129022890 @default.
• W3206496593 cites W3133896744 @default.

• next